Dual anti-HER2 blockade with directed monoclonal antibodies (mAbs) such as trastuzumab and pertuzumab has demonstrated strong clinical benefit for patients, and changed the paradigm of HER2+ breast cancer [42,68]. This evidence concerns the gene ERBB2 and breast carcinoma.